STAT+: Pharmalittle: Pharma and advocacy groups differ on vaccine equity; EC says Illumina-Grail deal breached merger rules

The pharma industry issued a “declaration” to work closer with intra-governmental groups to provide greater access to medicines and vaccines in future pandemics.

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation, especially since it appears there may be a benefit in doing so. Our choice today is maple bourbon. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …

Amid criticism over its approach to Covid-19, the pharmaceutical industry issued a new “declaration” to work closer with intra-governmental groups in order to provide greater access to medicines and vaccines in future pandemics, STAT says. Toward that end, the industry listed three priorities: enhance and streamline product development; speed manufacturing to generate high volumes of products; and allocate supplies to priority populations. But governments should widen clinical trial networks, boost regulatory approval strategies, fund pandemic preparedness and procurement mechanisms for low-income countries, not issue trade restrictions, and maintain intellectual property rights.

Continue to STAT+ to read the full story…